127 related articles for article (PubMed ID: 17308373)
1. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy.
Dixon A; Wells CC; Singh S; Babayan R; Maric C
Am J Nephrol; 2007; 27(2):120-8. PubMed ID: 17308373
[TBL] [Abstract][Full Text] [Related]
2. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy.
Mankhey RW; Bhatti F; Maric C
Am J Physiol Renal Physiol; 2005 Feb; 288(2):F399-405. PubMed ID: 15454392
[TBL] [Abstract][Full Text] [Related]
3. 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney.
Mankhey RW; Wells CC; Bhatti F; Maric C
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R769-77. PubMed ID: 16931652
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 fatty acid rich diet prevents diabetic renal disease.
Garman JH; Mulroney S; Manigrasso M; Flynn E; Maric C
Am J Physiol Renal Physiol; 2009 Feb; 296(2):F306-16. PubMed ID: 19052104
[TBL] [Abstract][Full Text] [Related]
5. 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling.
Dixon A; Maric C
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1678-90. PubMed ID: 17686959
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent effects of dihydrotestosterone in the streptozotocin-induced diabetic rat kidney.
Xu Q; Prabhu A; Xu S; Manigrasso MB; Maric C
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F307-15. PubMed ID: 19493965
[TBL] [Abstract][Full Text] [Related]
7. Diabetes modulates differentially creatine kinase-specific activity responsiveness to estradiol-17beta and to raloxifene in rat organs.
Somjen D; Shen M; Stern N; Mirsky N
J Cell Biochem; 2006 Sep; 99(1):133-9. PubMed ID: 16598752
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice.
Chin M; Isono M; Isshiki K; Araki S; Sugimoto T; Guo B; Sato H; Haneda M; Kashiwagi A; Koya D
Am J Pathol; 2005 Jun; 166(6):1629-36. PubMed ID: 15920148
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats.
Manigrasso MB; Sawyer RT; Hutchens ZM; Flynn ER; Maric-Bilkan C
Am J Physiol Renal Physiol; 2012 May; 302(9):F1203-9. PubMed ID: 22301628
[TBL] [Abstract][Full Text] [Related]
10. Diabetic nephropathy is associated with decreased circulating estradiol levels and imbalance in the expression of renal estrogen receptors.
Wells CC; Riazi S; Mankhey RW; Bhatti F; Ecelbarger C; Maric C
Gend Med; 2005 Dec; 2(4):227-37. PubMed ID: 16464734
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats.
Chung MT; Cheng PY; Lam KK; Chen SY; Ting YF; Yen MH; Lee YM
Menopause; 2010; 17(1):127-34. PubMed ID: 19745773
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of estradiol synthesis attenuates renal injury in male streptozotocin-induced diabetic rats.
Manigrasso MB; Sawyer RT; Marbury DC; Flynn ER; Maric C
Am J Physiol Renal Physiol; 2011 Sep; 301(3):F634-40. PubMed ID: 21653631
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats.
Esposito E; Iacono A; Raso GM; Pacilio M; Coppola A; Di Carlo R; Meli R
Endocrinology; 2005 Aug; 146(8):3301-8. PubMed ID: 15860553
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status.
Nishi Y; Satoh M; Nagasu H; Kadoya H; Ihoriya C; Kidokoro K; Sasaki T; Kashihara N
Kidney Int; 2013 Apr; 83(4):662-73. PubMed ID: 23344476
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis.
Zhou F; Dong H; Liu Y; Yan L; Sun C; Hao P; Liu Y; Zhai J; Liu Y
Brain Res Bull; 2018 Jun; 140():281-290. PubMed ID: 29807145
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
Lloberas N; Cruzado JM; Franquesa M; Herrero-Fresneda I; Torras J; Alperovich G; Rama I; Vidal A; Grinyó JM
J Am Soc Nephrol; 2006 May; 17(5):1395-404. PubMed ID: 16597691
[TBL] [Abstract][Full Text] [Related]
19. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds.
Yao Z; Shen X; Capodanno I; Donnelly M; Fenyk-Melody J; Hausamann J; Nunes C; Strauss J; Vakerich K
J Invest Surg; 2005; 18(4):177-83. PubMed ID: 16126628
[TBL] [Abstract][Full Text] [Related]
20. 17-beta Estradiol attenuates streptozotocin-induced diabetes and regulates the expression of renal sodium transporters.
Riazi S; Maric C; Ecelbarger CA
Kidney Int; 2006 Feb; 69(3):471-80. PubMed ID: 16514430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
